|
COPYRIGHT 2006 International Medical News Group
A Senate committee report showing that a vagus nerve stimulation device was approved for treatment-resistant depression over the objections of "more than 20 [Food and Drug Administration] scientists, medical officers, and management staff" could add to the difficulties patients and psychiatrists have reportedly had in securing insurance coverage for the device. The report, the culmination of a yearlong investigation by the Senate Finance Committee, said that given the findings, "it is questionable whether or not the VNS Therapy System for TRD met the agency's standard for...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
